, Proc. Natl Acad. Sci. USA, vol.101, pp.14631-14638, 2004.

P. G. Coulie, V. Brichard, and A. Van-pel, A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

, J. Exp. Med, vol.180, issue.1, pp.35-42, 1994.

Y. Kawakami, S. Eliyahu, and C. H. Delgado, Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor, Proc. Natl Acad. Sci. USA, vol.91, issue.9, pp.3515-3519, 1994.

V. Brichard, A. Van-pel, and T. Wolfel, The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

, J. Exp. Med, vol.178, issue.2, pp.489-495, 1993.

A. B. Bakker, M. W. Schreurs, and A. J. De-boer, Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumorinfiltrating lymphocytes, J. Exp. Med, vol.179, issue.3, pp.1005-1009, 1994.

Y. Godet, J. Desfrancois, and V. Vignard, Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy, Eur. J. Immunol, vol.40, issue.6, pp.1786-1794, 2010.

M. J. Pittet, A. Zippelius, and D. Valmori, Melan-A/MART-1-specific CD8 T cells: from thymus to tumor, Trends Immunol, vol.23, issue.7, pp.325-328, 2002.

A. Zippelius, M. J. Pittet, and P. Batard, Thymic selection generates a large T cell pool recognizing a self-peptide in humans, J. Exp. Med, vol.195, issue.4, pp.485-494, 2002.

D. C. Linehan, P. S. Goedegebuure, G. E. Peoples, S. O. Rogers, and T. J. Eberlein, Tumor-specific and HLA-A2-restricted cytolysis by tumorassociated lymphocytes in human metastatic breast cancer, J. Immunol, vol.155, issue.9, pp.4486-4491, 1995.

H. Ikeda, B. Lethe, and F. Lehmann, Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor, Immunity, vol.6, issue.2, pp.199-208, 1997.

M. Griffioen, J. H. Kessler, and M. Borghi, Detection and functional analysis of CD8 + T cells specific for PRAME: a target for T-cell therapy, Clin. Cancer Res, vol.12, issue.10, pp.3130-3136, 2006.

C. Quintarelli, G. Dotti, and B. Angelis, Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia, Blood, vol.112, issue.5, pp.1876-1885, 2008.

K. Rezvani, A. S. Yong, and A. Tawab, Ex vivo characterization of polyclonal memory CD8 + T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia, Blood, vol.113, issue.10, pp.2245-2255, 2009.

A. Mackensen, N. Meidenbauer, and S. Vogl, Phase I study of adoptive T-cell therapy using antigen-specific CD8 + T cells for the treatment of patients with metastatic melanoma, J. Clin. Oncol, vol.24, issue.31, pp.5060-5069, 2006.

N. Meidenbauer, J. Marienhagen, and M. Laumer, Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients, J. Immunol, vol.170, issue.4, pp.2161-2169, 2003.

M. E. Dudley, J. Wunderlich, and M. I. Nishimura, Adoptive transfer of cloned melanomareactive T lymphocytes for the treatment of patients with metastatic melanoma

, J. Immunother, vol.24, issue.4, pp.363-373, 2001.

A. Khammari, N. Labarriere, and V. Vignard, Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones, J. Invest. Dermatol, vol.129, issue.12, pp.2835-2842, 2009.

C. Yee, J. A. Thompson, and D. Byrd, Adoptive T cell therapy using antigen-specific CD8 + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells, Proc. Natl Acad. Sci. USA, vol.99, issue.25, pp.16168-16173, 2002.

M. E. Dudley, J. R. Wunderlich, and J. C. Yang, A Phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma, J. Immunother, vol.25, issue.3, pp.243-251, 2002.

R. B. Effros and G. Pawelec, Replicative senescence of T cells: does the Hayflick limit lead to immune exhaustion?, Immunol. Today, vol.18, issue.9, pp.450-454, 1997.

L. Gattinoni, D. J. Powell, S. A. Rosenberg, and N. P. Restifo, Adoptive immunotherapy for cancer: building on success, Nat. Rev. Immunol, vol.6, issue.5, pp.383-393, 2006.

C. S. Hinrichs, L. Gattinoni, and N. P. Restifo, Programming CD8 + T cells for effective immunotherapy, Curr. Opin. Immunol, vol.18, issue.3, pp.363-370, 2006.

. Overexpressing-telomerase,

, J. Immunol, vol.177, issue.6, pp.3657-3668, 2006.

T. N. Schumacher, T-cell-receptor gene therapy, Nat. Rev. Immunol, vol.2, issue.7, pp.512-519, 2002.

Z. Dembic, W. Haas, and S. Weiss, Transfer of specificity by murine a and b T-cell receptor genes, Nature, vol.320, issue.6059, pp.232-238, 1986.

T. M. Clay, M. C. Custer, and . Sachs, Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity, J. Immunol, vol.1163, issue.1, pp.507-513, 1999.

A. Calogero, G. A. Hospers, and K. M. Kruse, Retargeting of a T cell line by anti MAGE-3/HLA-A2 a b TCR gene transfer

, Anticancer Res, vol.20, issue.3A, pp.1793-1799, 2000.

K. Fujio, Y. Misaki, and K. Setoguchi, Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the a b TCR complex, J. Immunol, vol.165, issue.1, pp.528-532, 2000.

T. Stanislawski, R. H. Voss, and C. Lotz, Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer, Nat. Immunol, vol.2, issue.10, pp.962-970, 2001.

R. A. Morgan, M. E. Dudley, and J. R. Wunderlich, Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, vol.314, issue.5796, pp.126-129, 2006.

, nn First clinical study reporting the adoptive cell transfer of autologous PBL transduced with an allogeneic T-cell receptor gene, in metastatic melanoma patients

C. J. Cohen, Y. F. Li, and M. El-gamil, Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond, Cancer Res, vol.67, issue.8, pp.3898-3903, 2007.

C. J. Cohen, Y. Zhao, Z. Zheng, S. A. Rosenberg, and R. A. Morgan, Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability, Cancer Res, vol.66, issue.17, pp.8878-8886, 2006.

J. Kuball, M. L. Dossett, and M. Wolfl, Facilitating matched pairing and expression of TCR chains introduced into human T cells, Blood, vol.109, issue.6, pp.2331-2338, 2007.

G. Bialer, M. Horovitz-fried, &. Ya, and . Acobi, Selected murine residues endow human TCR with enhanced tumor recognition, J. Immunol, vol.184, issue.11, pp.6232-6241, 2010.

N. Chinnasamy, J. A. Wargo, and Y. Z. Rao, A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer, J. Immunol, vol.186, issue.2, pp.685-696, 2011.

Z. Eshhar, Tumor-specific T bodies: towards clinical application, Cancer Immunol. Immunother, vol.45, issue.3-4, pp.131-136, 1997.

B. Jena, G. Dotti, and L. Cooper, Redirecting T-cell specificity by introducing a tumorspecific chimeric antigen receptor, Blood, vol.116, issue.7, pp.1035-1044, 2010.

M. Cobbold, N. Khan, and B. Pourgheysari, Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers, J. Exp. Med, vol.202, issue.3, pp.379-386, 2005.

M. Bodinier, M. A. Peyrat, and C. Tournay, Efficient detection and immunomagnetic sorting of specific T cells using multimers of MHC class I and peptide with reduced CD8 binding, Nat. Med, vol.6, issue.6, pp.707-710, 2000.

, Describes an efficient method to sort antigen-specific T cells, based on a3-mutated HLA-A2 multimers coated on magnetic beads

N. Labarriere, N. Gervois, and A. Bonnin, PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting, Cancer Immunol. Immunother, vol.57, issue.2, pp.185-195, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00167752

R. Bouquie, A. Bonnin, and K. Bernardeau, A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes, Cancer Immunol. Immunother, vol.58, issue.4, pp.553-566, 2009.

F. G. Gao, V. Khammanivong, and W. J. Liu, Antigen-specific CD4 + T-cell help is required to activate a memory CD8 + T cell to a fully functional tumor killer cell, Cancer Res, vol.62, issue.22, pp.6438-6441, 2002.

H. M. Hu, H. Winter, W. J. Urba, and B. A. Fox, Divergent roles for CD4 + T cells in the priming and effector/memory phases of adoptive immunotherapy, J. Immunol, vol.165, issue.8, pp.4246-4253, 2000.

K. Hung, R. Hayashi, and A. Lafond-walker, The central role of CD4 + T cells in the antitumor immune response, J. Exp. Med, vol.188, issue.12, pp.2357-2368, 1998.

J. A. Keene and J. Forman, Helper activity is required for the in vivo generation of cytotoxic T lymphocytes, J. Exp. Med, vol.155, issue.3, pp.768-782, 1982.

F. Castellino and R. N. Germain, Cooperation between CD4 + and CD8 + T cells: when, where, and how, Annu. Rev. Immunol, pp.24519-540, 2006.

R. E. Toes, F. Ossendorp, R. Offringa, and C. J. Melief, CD4 T cells and their role in antitumor immune responses, J. Exp. Med, vol.189, issue.5, pp.753-756, 1999.

A. Schietinger, M. Philip, R. B. Liu, K. Schreiber, and H. Schreiber, Bystander killing of cancer requires the cooperation of CD4 + and CD8 + T cells during the effector phase, J. Exp. Med, vol.207, issue.11, pp.2469-2477, 2010.

S. A. Quezada, T. R. Simpson, and K. S. Peggs, Tumor-reactive CD4 + T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts, J. Exp. Med, vol.207, issue.3, pp.637-650, 2010.

C. A. Chambers, M. S. Kuhns, J. G. Egen, and J. P. Allison, CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy, Annu. Rev. Immunol, pp.19565-594, 2001.

P. Attia, G. Q. Phan, and A. V. Maker, Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4, J. Clin. Oncol, vol.23, issue.25, pp.6043-6053, 2005.

K. Sanderson, R. Scotland, and P. Lee, Autoimmunity in a Phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma, J. Clin. Oncol, vol.23, issue.4, pp.741-750, 2005.

T. L. Whiteside, Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression, Expert Opin. Biol. Ther, vol.10, issue.7, pp.1019-1035, 2010.

N. Koike, S. Pilon-thomas, and J. J. Mule, Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma, J. Immunother, vol.31, issue.4, pp.402-412, 2008.

B. Zhang, N. A. Bowerman, and J. K. Salama, Induced sensitization of tumor stroma leads to eradication of established cancer by T cells, J. Exp. Med, vol.204, issue.1, pp.49-55, 2007.

D. D. Vo, R. M. Prins, and J. L. Begley, Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824, Cancer Res, vol.69, issue.22, pp.8693-8699, 2009.